


532 Rec'd PCT/PTC 27 SEP 2000

FORM PTO-1390 (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEYS DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.51) 09/647327
INTERNATIONAL APPLICATION NO. PCT/GB99/00966	INTERNATIONAL FILING DATE March 26, 1999	PRIORITY DATE CLAIMED March 27, 1998	
TITLE OF INVENTION POLYMORPHISM II: LINKAGE OF ASTHMA TO A LOCUS ON CHROMOSOME 4			
APPLICANT(S) FOR DO/EO/US WILLIAM OSMOND CHARLES MICHAEL COOKSON; SUMIT BHATTACHARYYA; NICHOLAS LEAVES			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11. to 16. below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information: Courtesy copy of published PCT application</p>			

430 Rec'd PCT/PTO 27 SEP 2000

U.S. APPLICATION NO. 61/000,000 (37 CFR 1.53)		INTERNATIONAL APPLICATION NO. PCT/GB99/00966		ATTORNEY'S DOCKET NUMBER	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 *International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; height: 100px; width: 100%;"></div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	16 - 20 =		X \$18.00	\$	
Independent claims	2 - 3 =		X \$78.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$840	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$840	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$840	
				Amount to be:	\$
				refunded	\$
				charged	\$
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed.					
b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>20-1430</u> in the amount of \$ <u>840</u> to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>20-1430</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Joe Liebeschuetz Townsend and Townsend and Crew LLP Two Embarcadero Center, 8th fl. San Francisco, CA 94111				<div style="text-align: right;">  SIGNATURE: <u>Joe Liebeschuetz</u> NAME <u>37.505</u> REGISTRATION NUMBER </div>	

430 Rec'd PCT/PTO 27 SEP 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. National Phase of

PCT/GB99/00966 of:

William Osmond Charles Michael
Cookson et al.

Application No.: Unassigned

Filed: Herewith

For: POLYMORPHISM II: LINKAGE
OF ASTHMA TO A LOCUS ON
CHROMOSOME 4PRELIMINARY AMENDMENT

Box PCT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

IN THE CLAIMS:

Please amend claims 5, 6, 7, 8, 9, 10 and 16 as follows. All pending unamended claims have been reproduced in small type for ease of reference.

1. (As filed) A method for diagnosing an individual as being asthmatic, or as having a predisposition to asthma, which method comprises demonstrating in the individual the presence or absence of one or more alleles which are associated with asthma, wherein the one or more alleles which are associated with asthma, wherein the one or more alleles are situated at a locus in a region of chromosome 4 of up to 1 megabase in length, which region contains the locus D4S3032 and/or D4S2921.

2. (As filed) The method according to claim 1, wherein the method comprises the steps of:

- (i) obtaining a suitable tissue sample from the individual;
- (ii) preparing from the sample a nucleic acid sample;
- (iii) analyzing the nucleic acid sample for the presence or absence of the allele.

1 3. (As filed) The method according to claim 2, wherein prior to analysis, the locus at
2 which the or each allele is situated is amplified.

1 4. (As filed) The method according to claim 3, wherein the amplification is by the PCR.

1 5. (Amended) The method according to [any one of] claim[s] 1 [to 4],
2 wherein the locus at which the or each allele is situated comprises microsatellite repeats of
3 variable length.

1 6. (Amended) The method according to claim 3 [or claim 4], wherein the
2 amplification is performed using a pair of primers for each allele, wherein each primer in a pair
3 hybridizes under suitably stringent conditions to a region either side of the microsatellite
4 repeats.

1 7. (Amended) The method according to [any one of] claim[s] 1 [to 6],
2 wherein the allele for identification is D4S3032*5.

1 8. (Amended) The method according to [any one of] claim[s] 1 [to 6],
2 wherein the allele for identification is D4S2921*13.

1 9. (Amended) The method according to [any one of] claim[s] 1 [to 6],
2 wherein the alleles for identification are D4S3032*5 and D4S2921*13.

1 10. (Amended) The method according to [any one of] claim[s] 3 [to 9],
2 wherein the analysis is carried out by size separation of amplification products.

1 11. (As filed) The method according to claim 10, wherein the primers in the pair of
2 primers comprise the oligonucleotide sequences identified by SEQ ID NO: 1 and SEQ ID NO: 2 or substantially
3 similar sequences, for D4S3032*5; or identified by SEQ ID NO: 3 and SEQ ID NO: 4 or substantially similar
4 sequences, for D4S2921*13; or both of the aforementioned pairs of primers for both of the aforementioned
5 alleles.

1 12. (As filed) A pair of oligonucleotide primers for amplification of an allele which is
2 associated with asthma, which allele is situated at a locus in a region of chromosome 2 of up to 1 megabase in
3 length, which region contains the locus D4S3032 and/or D4S2921.

1 13. (As filed) The pair of oligonucleotide primers according to claim 12, one of which is
2 labeled with a detectable marker.

1 14. (Amended) The pair of oligonucleotides according to claim 12 [or claim
2 13], capable of hybridizing under suitably stringent conditions to a region either side of a
3 region of microsatellite repeats at D4S3032 or D4S2921.

1 15. (As filed) The pair of oligonucleotide primers according to claim 14, comprising the
2 oligonucleotide sequences identified by SEQ ID NO: 1 and SEQ ID NO: 2 or substantially similar sequences, for
3 D4S3032*5; or the oligonucleotide sequences identified by SEQ ID NO: 3 and SEQ ID NO: 4 or substantially
4 similar sequences, for D4S2921*13.

1 16. (Amended) An assay kit which comprises the pair of oligonucleotide
2 primers according to [any one of] claim[s] 12 [to 15].


REMARKS

Amendments to claims 5, 6, 7, 8, 9, 10, 14 and 16 have been made to remove
multiple claim dependency.

CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of
this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Telephone: (650) 326-2400
Facsimile: (650) 326-2422
JOL:dms
PA 3099569 v1

POLYMORPHISM II: LINKAGE OF ASTHMA TO A LOCUS ON CHROMOSOME 4

This invention is concerned with methods for the diagnosis of asthma and with materials and methods relating thereto.

5 Asthma is a disease which is becoming more prevalent and is the most common disease of childhood (1). Most asthma in children and young adults is initiated by IgE mediated allergy (atopy) to inhaled allergens such as house dust mite and cat dander. However, not all asthmatics are atopic, and most atopic individuals do not have asthma, so that factors in
10 addition to atopy are necessary to induce the disease (2,3). Asthma is strongly familial, and is due to the interaction between genetic and environmental factors. The genetic factors are thought to be variants of normal genes ("polymorphisms") which alter their function to predispose to asthma.

15 Asthma may be identified by recurrent wheeze and intermittent air flow limitation. An asthmatic tendency may be quantified by the measurement of bronchial hyper-responsiveness in which an individual's dose-response curve to a broncho-constrictor such as histamine or methacholine is constructed. The curve is commonly summarised by the dose
20 which results in a 20% fall in air flow (PD20) or the slope of the curve between the initial air flow measurement and the last dose given (slope). Asthma is accompanied by blood eosinophilia, and eosinophils are prominent in asthmatic airways.

 In the atopic response, IgE is produced by B-cells in response to
25 allergen stimulation. These antibodies coat mast cells by binding to the high affinity receptor for IgE (FcεRI). When a multivalent allergen binds to an IgE-coated mast cell, the cross-linking of adjacent IgEs by allergen initiates a series of cellular events leading to the destabilisation of the cell membrane

and release of inflammatory mediators. This results in mucosal inflammation, wheezing, coughing, sneezing and nasal blockage.

Atopy can be diagnosed by (i) a positive skin prick test in response to a common allergen; (ii) detecting the presence of specific serum
5 IgE for allergen; or (iii) by detecting elevation of total serum IgE.

Genetic factors underlying a disease may be identified through localisation to particular chromosomal regions by genetic linkage. Genetic linkage is established by the study of families. It relies on matching the inheritance of disease with genetic polymorphisms of known localisation
10 (known as "genetic markers"). In a complex disease such as asthma, genetic linkage will typically localise genes to within 10 - 20 Megabases (Mb) of DNA. A region of this size may contain 350 - 700 genes, and will be too large to permit immediate identification of the disease-causing gene.

Closer localisation of disease-causing genes may be
15 accomplished by the detection of associations between particular alleles and the disease phenotype. Over short segments of DNA, distinctive alleles of the individual polymorphisms will show non-random association with alleles of neighbouring polymorphisms. This phenomenon, known as "linkage disequilibrium" occurs over 50-500 Kilobases (Kb) of DNA. Linkage
20 disequilibrium may be detected by the study of individuals as well as by the study of families.

Disease-causing alleles will be in linkage disequilibrium with non-functional polymorphisms from the same chromosomal segment. It is therefore possible to detect allelic association with disease from particular
25 chromosomal segments, without identifying the exact polymorphism and gene underlying the disease state.

The detection of allelic association may therefore give information as to disease susceptibility in a particular individual. Furthermore,

allelic association is indicative of a disease-causing gene being present within 500 Kb of DNA in either direction from the allele (i.e. 1 Mb in total). Such a region may contain only 30 genes, within which the identification of the disease-causing gene is possible.

5 The presence of linkage disequilibrium also means that other polymorphisms may be anticipated to associate with disease, and that these additional polymorphisms will also be diagnostic of disease susceptibility in particular individuals.

Genetic associations with atopy have been demonstrated.

10 WO 95/05481 discloses that variants of the gene encoding the β -subunit of the high-affinity receptor for IgE (Fc ϵ RI β) are associated with atopy. It teaches a method for diagnosing atopy which is based upon the demonstration of the presence or absence of one of two variants in a specific portion of the DNA sequence of the gene encoding Fc ϵ RI β , located near the
15 commencement of exon 6 of the Fc ϵ RI β gene on chromosome 11. A further variant has also been found in which the unusual variant sequence is in the coding sequence for the C-terminal cytoplasmic tail of Fc ϵ RI β (4).

20 Tumour Necrosis Factor (TNF) is a pro-inflammatory cytokine that is found in increased concentration in asthmatic airways (5). We have previously shown that polymorphisms within the TNF gene are associated with an increased risk of asthma (6).

25 The known polymorphisms do not account for all of the genetic factors which predispose to asthma. In particular, asthma is not necessarily an atopic disease. Identification of further genetic polymorphisms linked to asthma will allow the identification of children at risk of asthma before the disease has developed (for example immediately after birth), with the potential for prevention of disease. The presence of particular polymorphisms may predict the clinical course of disease (e.g. severe as opposed to mild) or the

response to particular treatments. This diagnostic information will be of use to the health care, pharmaceutical and insurance industries.

We have previously established linkage of bronchial hyper-responsiveness to chromosome 4 (8). However, this finding is of no use in
5 diagnosis.

It has now been discovered that a genetic polymorphism known as D4S3032*5 on chromosome 4 and a nearby polymorphism known as D4S2921*13 are associated with asthmatic traits. Specifically, D4S3032*5 is associated with bronchial hyper-responsiveness and D4S2921*13 is
10 associated with peripheral eosinophilia, both of these being traits which underlie asthma. The two polymorphisms can therefore be used as diagnostic tools.

The invention therefore provides a method for diagnosing an individual as being asthmatic, or as having a predisposition to asthma, which
15 method comprises demonstrating in the individual the presence or absence of one or more alleles which are associated with asthma, wherein the one or more alleles are situated at a locus in a region of chromosome 4 of up to 1 megabase in length, which region contains the locus D4S3032 and/or D4S2921.

20 The 1Mb region of chromosome 4 referred to flanks the D4S3032 and D4S2921 loci. Thus, the specific allele D4S3032*5, or D4S2921*13, or other unusual polymorphisms in the region which are associated with asthma, may be the subject of identification in the method according to the invention. Equally two or more such alleles may be the
25 subject of identification, including in particular the combination of D4S3032*5 and D4S2921*13.

Current diagnostic methods involving detection at the nucleic acid level normally comprise the steps of:

- (i) obtaining a suitable tissue sample from the individual;
- (ii) preparing from the tissue sample a nucleic acid sample;
- (iii) analysing the nucleic acid sample for the presence or absence of the relevant nucleic acid sequence, such as a specific allele.

5

Preferably, an amplification step is performed prior to the analysis, such that the locus at which the allele is situated is amplified. A preferred amplification technique is the PCR, although any suitable method of nucleic acid amplification may be employed.

10

In further aspects, the invention provides a pair of oligonucleotide primers for amplification of an allele which is associated with asthma, which allele is situated at a locus in a region of chromosome 4 of up to 1 megabase in length, which region contains the locus D4S3032 and/or D4S2921; and an assay kit comprising the pair of oligonucleotide primers.

15

The specific allele for identification may take the form of microsatellite repeats, which are nucleotide sequences containing short, repeated nucleotide motifs, usually a dinucleotide or a trinucleotide motif. A pair of primers which hybridize under suitably stringent conditions, to sequences at a position on either side of the microsatellite repeats, may be used to amplify the microsatellite repeats by PCR. Differences in the number of repeats are recognised by size differences in the PCR products. An allele which has a specified number of repeats and therefore a known size can thus be identified. D4S3032*5 and D4S2921*13 are examples of such alleles.

20

The primers employed in the method comprise nucleic acid sequences which are complementary to, or substantially complementary to unique sequences either side of the microsatellite repeats, such that only the relevant polymorphic region of the genome is amplified. The conditions under which the amplification is performed are gauged such that specific

25

hybridization of the primers to the flanking sequences occurs and non-specific hybridization is avoided. The hybridization conditions are suitably stringent for that purpose. Standard techniques can be used to identify an appropriate set of reaction conditions.

5 Typically, the PCR products are detected by means of a detectable label attached to one of the PCR primers. Alternatively another form of labeling may be used such as a labeled sequence specific probe which hybridizes to the amplified sequences. The label may be a fluorescent or other label. The PCR products are subjected to size determination,
10 typically involving size-separation for example by gel electrophoresis, and the presence or absence of the allele of interest is determined.

 It will be evident that the invention is not limited with regard to the manner in which the presence or absence of the allele of interest is determined. The labeling, detection, separation or any other aspect of the
15 method as described here may be replaced by other suitable known techniques and reagents.

 The allele for identification may be an allele other than D4S3032*5 or D4S2921*13 which is in linkage disequilibrium with D4S3032*5 or D4S2921*13 and is associated with asthma. This includes alleles of both
20 functional and non-functional polymorphisms. Functional polymorphisms include polymorphisms within genes, usually within coding sequences of genes. Non-functional polymorphisms are polymorphisms which do not themselves cause the disease.

 This invention will now be further described in the Examples
25 section which follows. The Examples are intended to be illustrative and do not limit the scope of the invention in any way.

EXAMPLES

Description of Laboratory Testing

Subjects

Two panels of subjects have been studied.

5 Panel A consisted of 80 nuclear families sub-selected from an Australian population sample of 230 families (8). The panel contained a total of 203 offspring forming 172 sib-pairs. 12% of the children were asthmatic.

Panel C consisted of 87 nuclear families recruited through a child attending an asthma clinic in the Oxford region. The families contained
10 216 offspring (148 sibling pairs), of whom 44% were asthmatic.

Phenotyping

 Bronchial responsiveness to methacholine was measured as previously described (8): the maximum dose administered was 12 μ mol. The
15 slope of the dose-response curve was calculated as (pre-dose forced expiratory volume in one second (FEV1) - last FEV1) \div the cumulative dose of methacholine). A constant of 0.01 was added to each measurement, to allow loge transformation when Slope was ≤ 0 . Eosinophils in peripheral blood were
 Coulter-counted and the values log_e transformed before analysis.

20

Genotyping

 The microsatellite markers D4S3032 and D4S2921 were typed by semi-automated fluorescent methods, as described previously (8). These markers are in close proximity at the telomeric region of the long arm of
25 chromosome 4.

 The polymerase chain reaction primer sequences for the markers were as follows:

D4S3032 5' TGA AAT TCT ATT GAC CAA TGA TGT G (SEQ ID NO: 1)

UD4S3032 5' TAG CAC CTG GAT TTA CCA TGA C (SEQ ID NO: 2)

D4S2921 5' TCC TTC AGG AAC TGG TG (SEQ ID NO: 3)

UD4S2921 5' TTA AAA ATC TAC AGA CAA GGG C (SEQ ID NO: 4)

5 The polymerase chain reaction conditions were as follows: The reaction volumes were 10 μ l, containing 50ng of genomic DNA, 200mM dNTPs, 1 x NH₄⁺ buffer, 50ng oligonucleotide primers (forward labelled fluorescently), 0.5 to 3.0mM MgCl₂ and 0.2U Taq polymerase. Cycling conditions were 1 min at 95°C, 1 min at 55°C and 45s at 72°C; 28 cycles were
10 used. PCRs were performed on an Hybaid Omnigene thermal cycler.

Electrophoresis and allele scoring were as follows:

PCR products were mixed with a size standard (GS350 TAM) in loading buffer (80% (v/v) formamide, 20% (v/v) 50mM EDTA, 0.1% (w/v) blue dextran).

15 Samples were denatured at 95°C for 4 min immediately prior to loading onto a 6% polyacrylamide gel and were electrophoresed at 800v for 6h on an Applied Biosystems (ABI) 313 DNA sequencer. Allele sizes were assigned using the ABI GENESCAN and ABI GENOTYPER software.

Association Analysis

20 Association was tested against the phenotype of bronchial hyper-responsiveness and peripheral blood eosinophil counts by the ASSOC routine of the SAGE (ver2.2) computer program.

Results

25

Association with D4S3032 allele 5 and D4S2921 allele 13

Each of the markers was then tested for association with the asthma phenotype. Association was seen in panel A for allele 5 of D4S3032

(D4S3032*5) and bronchial hyper-responsiveness. This allele is 145 base pairs in size, using the primers described above. Association between allele 13 of D4S2921 (D4S2921*13) and eosinophil counts were seen in both panels. This allele is 162 base pairs in size, using the primers described
 5 above. (Other suitable primers can be designed and their amplification product size determined for D4S3032*5 or D4S2921*13, using known sequence information (9).) The results of testing were as follows:

Trait	Marker	Allele	Panel A		Panel C		Combined	
			χ^2	p	χ^2	p	χ^2	p
Slope	d4s3032	5	13.56	0.0002	-	-	-	-
Eosinophils	d4s2921	13	5.00	0.03	11.17	0.0008	17.61	0.0000

10 The recombination fraction between D4S3032 and D4S2921 was 3%, indicating in this telomeric region that the distance between the markers is of the order of 0.5 to 1 megabase.

The results indicate that D4S3032*5 and D4S2921*13 show strong association with intermediate phenotypes underlying asthma in two
 15 diverse panels of subjects. It may therefore be inferred that a gene influencing asthma is present within 500 kilobases in either direction of D4S3032 and D4S2921.

20 REFERENCES

1. Strachan, D.P., Anderson, H.R., Limb, E.S., O'Neill, A. and Wells, N. (1994). A national survey of asthma prevalence, severity, and treatment in Great Britain. *Arch. Dis. Child.*, 70, 174-178.

2. Fraser, R.S., Paré, J.A.P., Fraser, R.G. and Paré, P.D., eds. (1994) Synopsis of Diseases of the Chest. WB Saunders Company, Philadelphia: 635-53.
3. Djukanovic, R., Roche, W.R., Wilson, J.W., Beasley, C.R., Twentyman,
5 O.P., Howarth, R.H. and Holgate S.T. (1990) Mucosal inflammation in asthma. *Am. Rev. Respir. Dis.*, **142**, 434-457.
4. Hill, M.R. and Cookson, W.O.C.M. (1996). A new variant of the β subunit of the high-affinity receptor for Immunoglobulin E (Fc ϵ RI- β E237G): Associations of measures of atopy and bronchial hyper-responsiveness. *Hu.*
10 *Mol. Gen.* **5**, 959-962.
5. Broide, D.H., Lotz, M., Cuomo, A.J., Coburn, D.A., Federman, E.C. and Wasserman, S.I. (1992) Cytokines in symptomatic asthma airways. *J. Allergy Clin. Immunol.* **89**, 958-967.
6. Moffatt M.P, Cookson WOCM. Tumour Necrosis Factor Haplotypes.
15 and Asthma. *Hum Molec Genet* 1997; **6**: 551-554.
7. Bailly S, di Giovine FS, Blakemore A.I.F, Duff G.W. Genetic polymorphism of human interleukin-1 α . *Eur J Immunol* 1993; **23**: 1240-1245.
8. Daniels S.E, Bhattacharyya S, James A, Leaves N.I, Young A, Hill M.R, Faux J.A, Ryan G.F, le Söuef P.N, Lathrop G.M, Musk A.W, Cookson
20 W.O.C.M. A genome-wide search for quantitative trait loci underlying asthma. *Nature* 1996; **383**: 247-250.
9. Dib S. et al. A comprehensive map of the human genome based on 5264 microsatellites. *Nature* 1996; **380**: 152-154.

CLAIMS

1. A method for diagnosing an individual as being asthmatic, or as having a predisposition to asthma, which method comprises demonstrating in
5 the individual the presence or absence of one or more alleles which are associated with asthma, wherein the one or more alleles are situated at a locus in a region of chromosome 4 of up to 1 megabase in length, which region contains the locus D4S3032 and/or D4S2921.
2. The method according to claim 1, wherein the method comprises
10 the steps of:
 - (i) obtaining a suitable tissue sample from the individual;
 - (ii) preparing from the tissue sample a nucleic acid sample;
 - (iii) analysing the nucleic acid sample for the presence or absence of the allele.
- 15 3. The method according to claim 2, wherein prior to analysis, the locus at which the or each allele is situated is amplified.
4. The method according to claim 3, wherein the amplification is by the PCR.
5. The method according to any one of claims 1 to 4, wherein the
20 locus at which the or each allele is situated comprises microsatellite repeats of variable length.
6. The method according to claim 3 or claim 4, wherein the amplification is performed using a pair of primers for each allele, wherein each primer in a pair hybridises under suitably stringent conditions to a region either
25 side of the microsatellite repeats.
7. The method according to any one of claims 1 to 6, wherein the allele for identification is D4S3032*5.

8. The method according to any one of claims 1 to 6, wherein the allele for identification is D4S2921*13.
9. The method according to any one of claims 1 to 6, wherein the alleles for identification are D4S3032*5 and D4S2921*13.
- 5 10. The method according to any one of claims 3 to 9, wherein the analysis is carried out by size separation of amplification products.
11. The method according to claim 10, wherein the primers in the pair of primers comprise the oligonucleotide sequences identified by SEQ ID NO: 1 and SEQ ID NO: 2 or substantially similar sequences, for D4S3032*5; or identified by SEQ ID NO: 3 and SEQ ID NO: 4 or substantially similar sequences, for D4S2921*13; or both of the aforementioned pairs of primers for both of the aforementioned alleles.
- 10 12. A pair of oligonucleotide primers for amplification of an allele which is associated with asthma, which allele is situated at a locus in a region of chromosome 2 of up to 1 megabase in length, which region contains the locus D4S3032 and/or D4S2921.
- 15 13. The pair of oligonucleotide primers according to claim 12, one of which is labeled with a detectable marker.
14. The pair of oligonucleotides according to claim 12 or claim 13, capable of hybridising under suitably stringent conditions to a region either side of a region of microsatellite repeats at D4S3032 or D4S2921.
- 20 15. The pair of oligonucleotide primers according to claim 14, comprising the oligonucleotide sequences identified by SEQ ID NO:1 and SEQ ID NO:2 or substantially similar sequences, for D4S3032*5; or the oligonucleotide sequences identified by SEQ ID NO: 3 and SEQ ID NO:4 or substantially similar sequences, for D4S2921*13.
- 25 16. An assay kit which comprises the pair of oligonucleotide primers according to any one of claims 12 to 15.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68	A1	(11) International Publication Number: WO 99/50449 (43) International Publication Date: 7 October 1999 (07.10.99)
<p>(21) International Application Number: PCT/GB99/00966</p> <p>(22) International Filing Date: 26 March 1999 (26.03.99)</p> <p>(30) Priority Data: 9806653.3 27 March 1998 (27.03.98) GB</p> <p>(71) Applicant (for all designated States except US): ISIS INNOVATION LIMITED [GB/GB]; 2 South Parks Road, Oxford OX1 3UB (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): COOKSON, William, Osmond, Charles, Michael [GB/GB]; 67 Hilltop Road, Oxford OX4 1PD (GB). BHATTACHARYYA, Sumit [GB/GB]; 20 Bury Road, Stapleford, Cambridgeshire CB2 5BP (GB). LEAVES, Nicholas [GB/GB]; 47 Burdell Avenue, Sandhills, Oxford OX3 8EE (GB).</p> <p>(74) Agent: PRIVETT, Kathryn, Louise; Stevens, Hewlett & Perkins, 1 Serjeants' Inn, Fleet Street, London EC4Y 1NT (GB).</p>		<p>(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: POLYMORPHISM II: LINKAGE OF ASTHMA TO A LOCUS ON CHROMOSOME 4</p> <p>(57) Abstract</p> <p>A method for diagnosing an individual as being asthmatic, or as having a predisposition to asthma is described, which method comprises demonstrating in the individual the presence or absence of one or more alleles which are associated with asthma, wherein the one or more alleles are situated at a locus in a region of chromosome 4 of up to 1 megabase in length, which region contains the locus D4S3032 and/or D4S2921.</p> <p style="text-align: center;">COPY</p>		

WENDEROTH, LIND & PONACK, L.L.P.
2033 K Street, N.W., Suite 800
Washington, D.C. 20006

WENDEROTH, LIND & PONACK, L.L.P.
Area Code (202) 721-8200

Direct Facsimile Messages to:
Area Code (202) 721-8250

Full Name of First Inventor	FAMILY NAME <u>COOKSON</u>	FIRST GIVEN NAME <u>William</u>	SECOND GIVEN NAME <u>Osmond Charles Michael</u>
Residence & Citizenship	CITY <u>Oxford</u>	STATE OR COUNTRY <u>Great Britain</u> <i>GBN</i>	COUNTRY OF CITIZENSHIP <u>Great Britain</u>
Post Office Address	ADDRESS <u>67 Hilltop Road</u>	CITY <u>Oxford</u>	STATE OR COUNTRY <u>Great Britain</u> ZIP CODE <u>OX4 1PD</u>
Full Name of Second Inventor	FAMILY NAME <u>BHATTACHARYYA</u>	FIRST GIVEN NAME <u>Sumit</u>	SECOND GIVEN NAME
Residence & Citizenship	CITY <u>Stapleford, Cambridgeshire</u>	STATE OR COUNTRY <u>Great Britain</u> <i>GBN</i>	COUNTRY OF CITIZENSHIP <u>Great Britain</u>
Post Office Address	ADDRESS <u>20 Bury Road</u>	CITY <u>Stapleford, Cambridgeshire</u>	STATE OR COUNTRY <u>Great Britain</u> ZIP CODE <u>CB2 5BP</u>
Full Name of Third Inventor	FAMILY NAME <u>LEAVES</u>	FIRST GIVEN NAME <u>Nicholas</u>	SECOND GIVEN NAME
Residence & Citizenship	CITY <u>Sandhills, Oxford</u>	STATE OR COUNTRY <u>Great Britain</u> <i>GBN</i>	COUNTRY OF CITIZENSHIP <u>Great Britain</u>
Post Office Address	ADDRESS <u>47 Burdell Avenue</u>	CITY <u>Sandhills, Oxford</u>	STATE OR COUNTRY <u>Great Britain</u> ZIP CODE <u>OX3 8EE</u>
Full Name of Fourth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Fifth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Sixth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor	<u>William Osmond Charles Michael COOKSON</u>	Date	<u>23.01.01</u>	X
2nd Inventor	<u>Sumit BHATTACHARYA</u>	Date	<u>14/2/01</u>	X
3rd Inventor	<u>Nicholas LEAVES</u>	Date	<u>31.1.01</u>	X
4th Inventor		Date		
5th Inventor		Date		
6th Inventor		Date		

The above application may be more particularly identified as follows:

U.S. Application Serial No. 09/647,327 Filing Date September 27, 2000

Applicant Reference Number P30625US/KVC/PS/CF Atty Docket No. 2000-1720

Title of Invention POLYMORPHISM II: LINKAGE OF ASTHMA TO A LOCUS ON CHROMOSOME 4

277

Rev. 11-3/98

Effective March 1998

DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

(X) Original () Supplemental () Substitute () PCT () DESIGN

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: POLYMORPHISM II: LINKAGE OF ASTHMA TO A LOCUS ON CHROMOSOME 4

of which is described and claimed in:

() the attached specification, or

(X) the specification in application Serial No. 09/647,327, filed September 27, 2000, and with amendments through (if applicable), or

() the specification in International Application No. , filed , and as amended on (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Great Britain	9806653.3	March 27, 1998	Yes

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

And I hereby appoint Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Jeffrey Nolton, Reg. No. 25,408; Warren M. Cheek, Jr., Reg. No. 33,367; Nils Pedersen, Reg. No. 33,145; and Charles R. Watts, Reg. No. 33,142, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., jointly and severally, attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys named herein to accept and follow instructions from Kilburn and Strode as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Send Correspondence to

Direct Telephone Calls to: